<DOC>
	<DOCNO>NCT02253251</DOCNO>
	<brief_summary>The investigator recruit enroll individual may KRAS-variant microRNA bind site mutation join registry study . The investigator allow individual obtain result physician completion study . The investigator current focus breast cancer .</brief_summary>
	<brief_title>Clinical Validation Role microRNA Binding Site Mutations Cancer Risk , Prevention Treatment</brief_title>
	<detailed_description>The investigator identify germ-line microRNA bind site mutation predict increase risk cancer , endometriosis associate infertility , unique tumor biology response treatment . The goal protocol determine mechanism mutation , KRAS-variant , association human health , cancer . The investigator collect saliva sample individual patient eligible choose enroll study , test KRAS-variant and/or mutation study . With specific permission , investigator keep excess DNA investigate discover additional similar mutation . The investigator purpose participant answer questionnaire lifestyle factor ongoing manner , understand impact different factor cancer risk patient mutation .</detailed_description>
	<criteria>Personal family history cancer Younger 18 Nonenglish speaking unable understand sign consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Cancer Risk</keyword>
	<keyword>Family Breast Ovarian Cancer</keyword>
	<keyword>Genetic Cancer Risk</keyword>
	<keyword>Cancer Treatment</keyword>
	<keyword>Familial multiple primary cancer risk</keyword>
</DOC>